1. Home
  2. BIVI

as 09-12-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Founded: 2013 Country:
United States
United States
Employees: N/A City: CARSON CITY
Market Cap: 11.9M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 316.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -12.12 EPS Growth: N/A
52 Week Low/High: $1.42 - $75.00 Next Earning Date: 11-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

BIVI Daily Stock ML Predictions

Stock Insider Trading Activity of BioVie Inc. (BIVI)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
DO CUONG V BIVI President & CEO Aug 7 '25 Buy $0.00 5,000 $0.00 9,992

Share on Social Networks: